However, the alterations in immune function, splenic antioxidant status, blood cell populations, and immune-related gene expression were notably restored in the FTN + CML-CNP-treated group. The gene discussed is CNP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.